Trials / Completed
CompletedNCT05401149
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Effectiveness and Safety of IV Rt-PA Treatment in Chinese AIS Patients Aged Above 80 Years: a Real-world Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,058 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment within 4.5 hours of symptom onset in a real-world clinical setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rt-PA | Recombinant Tissue Plasminogen Activator |
Timeline
- Start date
- 2022-07-18
- Primary completion
- 2022-12-14
- Completion
- 2022-12-14
- First posted
- 2022-06-02
- Last updated
- 2024-10-17
- Results posted
- 2024-10-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05401149. Inclusion in this directory is not an endorsement.